Market Overview

SFC Fluidics, Inc. Announces Partnership with JDRF to Develop Patch Pump with Open-Protocol Communication


SFC Fluidics, Inc. (SFC), a medical technology company, today announced
a new Industry Discovery and Development Partnership supported by JDRF,
the leading global organization funding type 1 diabetes (T1D) research.

This press release features multimedia. View the full release here:

In line with JDRF's goal to discover, develop, and deliver advances that
reduce the burden of T1D and expand access to and adoption of automated
insulin delivery (AID) technologies, JDRF will provide funding to SFC
for the development of an insulin patch pump with open-protocol
communication capabilities. JDRF launched its Open-Protocol Automated
Insulin Delivery (AID) Systems Initiative in 2017 with the goal to work
with key stakeholders to understand the regulatory and liability
implications of an "open-protocol" AID ecosystem – in which AID
components may be seamlessly and safely interoperable – and moreover to
accelerate the delivery of such components to market. The development
and delivery to market of a fully interoperable, open-protocol insulin
pump is the goal of this JDRF-SFC partnership.

Insulin-dependent diabetes impacts more than six million Americans, the
vast majority of whom are not reaching clinical targets for optimal
glucose levels. Insulin is a life-saving drug but needs to be dosed
accurately and safely to avoid serious adverse events.

The two-year funding commitment from JDRF enables SFC to accelerate the
development and regulatory submission of an open-protocol patch pump
system that enable seamless, secure connectivity with other devices
(e.g., by using Bluetooth technology) such as interoperable continuous
glucose monitors (CGMs) and third-party AID algorithms. Such algorithms
may include solutions developed in recent years by the do-it-yourself
(DIY) community, a following which is steadily gaining traction.

The foundation of SFC's insulin delivery technology, covered by several
issued and applied-for patents, is its inherently small size and
capability to deliver highly accurate doses of insulin. SFC will develop
a fully functional patch pump that will operate on its own platform as
well as publish its communication protocol so that approved devices can
communicate with the patch pump.

"There is a passionate group of people behind a patient-driven
ecosystem, using do-it-yourself (DIY) approaches to develop solutions to
meet their needs. We believe SFC's unique pumping technology will
provide new options for them to live the lifestyle that suits them the
best," said Anthony Cruz, CEO of SFC Fluidics. "With our partnership
with JDRF, we will bring new and innovative solutions to the diabetes

"We are excited to support SFC in its open-protocol pump development as
a key step toward the realization of our goal of an open-protocol AID
ecosystem," said Daniel Finan, JDRF Research Director. "We are hopeful
that solutions such as this will greatly expand choice in the
marketplace, increase adoption of advanced, life-improving technologies
among people with T1D, and accelerate the cadence of innovation in these
treatment options."

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D)
research. Our mission is to accelerate life-changing breakthroughs to
cure, prevent and treat T1D and its complications. To accomplish this,
JDRF has invested more than $2 billion in research funding since our
inception. We are an organization built on a grassroots model of people
connecting in their local communities, collaborating regionally for
efficiency and broader fundraising impact, and uniting on a national
stage to pool resources, passion, and energy. We collaborate with
academic institutions, policymakers, and corporate and industry partners
to develop and deliver a pipeline of innovative therapies to people
living with T1D. Our staff and volunteers throughout the United States
and our six international affiliates are dedicated to advocacy,
community engagement and our vision of a world without T1D. For more
information, please visit
or follow us on Twitter: @JDRF.

About SFC Fluidics, Inc.

SFC Fluidics, Inc. has a mission to advance healthcare and improve
quality of life through our enabling microfluidic technologies. The
company's vision is to become a recognized global leader in drug
delivery, with a focus on insulin, and health monitoring markets where
our unique product lines improve lifestyle and affordability. SFC
Fluidics® is a VIC
Technology Venture Development™
portfolio company. For more
information, please visit
or follow us on Twitter: @sfcfluidics.

View Comments and Join the Discussion!